Business
Veracyte Announces New Real-World Data Reinforcing the Potential Clinical Value of Percepta and Envisia Classifiers to Improve Diagnosis of Serious Lung Diseases
ePosters presented during ATS 2020 Virtual conference SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) announced today that data
About this update from Veracyte, Inc.
[{"type":"text","content":"\nePosters presented during ATS 2020 Virtual conference\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\n\nVeracyte, Inc. (Nasdaq: VCYT) announced today that data presented at the American Thoracic Society 2020 Virtual conference reinforce the potential clinical value of the company’s advanced genomic tests in diagnosing serious lung diseases. The data, presented in three ePosters, demonstrate how Veracyte’s Percepta Genomic Sequencing Classifier and Envisia Genomic Classifier may improve upon the diagnostic standard of care in lung cancer and idiopathic pulmonary fibrosis (IPF), respectively.\n\n\nLung cancer is the leading cause of cancer deaths, and will kill approximately 136,000 Americans this year – more than the next three leading cancers combined. Lung nodules are typically the first sign of lung cancer, however, determining which lung nodules are cancerous and which are benign is often challenging, leading to unnecessary invasive procedures or delayed treatment.\n\n\nVeracyte’s Percepta GSC helps guide next steps when bronchoscopy results are inconclusive. Patients deemed low-risk for cancer by the test can be monitored and those who are high-risk can proceed to further work-up.\n\n\nIn a study presented at ATS 2020, researchers evaluated the sensitivity of bronchoscopy alone, the Percepta GSC, and the Percepta GSC combined with bronchoscopy in detecting malignant lung nodules among 44 patients with low or intermediate pre-test risk of cancer. The overall sensitivity of bronchoscopy alone was 40.9 percent, compared to 92.3 percent for the Percepta GSC and 95.5 percent for bronchoscopy and the classifier combined.\n\n\n“These findings suggest that the Percepta GSC substantially increases the sensitivity of bronchoscopy in detecting cancer among lung nodules that are indeterminate following clinical work-up,” said Travis Dotson, M.D., associate professor, Wake Forest Baptist Health, who presented the data. “This enhanced diagnostic capability can help physicians more confidently determine which patients need further diagnostic procedures and which can simply be monitored over time.”\n\n\nIn two additional ATS 2020 ePoster presentations, researchers shared data from two prospective studies evaluating Veracyte’s Envisia Genomic Classifier in the diagnosis of IPF. Each year in the United States and Europe, up to 220,000 p...